Ensysce Biosciences to Present at the Janney Healthcare Conference 2019
SAN DIEGO--(BUSINESS WIRE)-- Ensysce Biosciences, Inc., a clinical stage drug delivery company, focusing on reducing deaths from opioid use, today announced that D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, will present at the Janney Healthcare Conference 2019 in New York on Monday September 9, at 8:15 am EST. Dr. Kirkpatrick will discuss the company’s two new classes of opioids, TAAP™ and MPAR™ technologies that can help to prevent the current crises of prescription drug abuse and overdose.
About Ensysce Biosciences
Ensysce has a mission to provide patients access to safer analgesia. One of our beliefs is that opioids are a vital element in medical therapy. Ensysce’s two unique technologies, TAAP™ and MPAR™, were designed to prevent drug abuse and prevent overdose, and the company’s first application of these technologies is for opioids.
PF614-TAAPTM – a new class of opioids.
The issue of manipulation of Abuse Deterrent Formulation (ADF) opioids, coupled with a desire to tackle the opioid crisis in a disruptive way, led Ensysce to develop a new TAAP™ (Trypsin Activated Abuse Protection) class of opioids, the first in class being PF614. PF614, a TAAP™ product providing extended release oxycodone, has been validated in a Phase 1 trial that demonstrated highly efficient release of oxycodone following oral administration along with an excellent safety profile. With the potential to develop PF614 through the 505(b)(2) regulatory pathway and Fast Track Status, Ensysce’s first product has a shortened timeline to registration and could be on the market as soon as 2022.
PF614-MPAR™ – the next generation of agent to eliminate overdose.
There is currently no treatment for pain which has built-in overdose protection. Ensyscse has addressed this with its Multi Pill Abuse Protection (MPAR™) technology. MPAR™ renders the activation agent inert when too many tablets are ingested, and the technology can be applied to most prescription drugs. The National Institute on Drug Abuse in 2018 supported the development of PF614-MPAR™ with a 4-year multi-million dollar award.
The Ensysce TAAP™ and MPAR™ overdose resistant platforms have worldwide intellectual patent protection, and have been applied to opioid, ADHD and opioid-use-disorder prescription drugs. Abuse of prescription drug is the fastest growing problem in the U.S. and it leads to billions in healthcare costs annually. For additional information about Ensysce Biosciences please visit www.ensysce.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005180/en/
D. Lynn Kirkpatrick, Ph.D.
CEO
Ensysce Biosciences Inc.
858-242-1553
lkirkpatrick@ensysce.com
Source: Ensysce Biosciences, Inc.
Released September 3, 2019